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High glucose transactivates the EGF receptor and up-regulates
serum glucocorticoid kinase in the proximal tubule.
Background. Serum glucocorticoid regulated kinase (SGK-
1) is induced in the kidney in diabetes mellitus. However, its
role in the proximal tubule is unclear. This study determined the
expression and functional role of SGK-1 in PTCs in high glucose
conditions. As the epidermal growth factor (EGF) receptor is
activated by both EGF and other factors implicated in diabetic
nephropathy, the relationship of SGK-1 with EGFR activity was
assessed.
Methods. mRNA and protein expression of SGK-1 and
mRNA expression of the sodium hydrogen exchanger NHE3
were measured in human PTCs exposed to 5 mmol/L (con-
trol) and 25 mmol/L (high) glucose. The effects of SGK-1 on
cell growth, apoptosis, and progression through the cell cycle
and NHE3 mRNA were examined following overexpression
of SGK-1 in PTCs. The role of EGFR activation in observed
changes was assessed by phospho-EGFR expression, and re-
sponse to the EGFR blocker PKI166. SGK-1 expression was
then assessed in vivo in a model of streptozotocin-induced dia-
betes mellitus type 2.
Results. A total of 25 mmol/L glucose and EGF (10 ng/mL)
increased SGK-1 mRNA (P < 0.005 and P < 0.002, respec-
tively) and protein (both P < 0.02) expression. High glucose and
overexpression of SGK-1 increased NHE3 mRNA (P < 0.05)
and EGFR phosphorylation (P < 0.01), which were reversed
by PKI166. SGK-1 overexpression increased PTC growth (P <
0.0001), progression through the cell cycle (P < 0.001), and in-
creased NHE3 mRNA (P < 0.01), which were all reversed with
PKI166. Overexpression of SGK-1 also protected against apop-
tosis induced in the PTCs (P < 0.0001). Up-regulation of tubular
SGK-1 mRNA in diabetes mellitus was confirmed in vivo. Oral
treatment with PKI166 attenuated this increase by 51%. No
EGF protein was detectable in PTCs, suggestive of phosphory-
lation of the EGFR by high glucose and downstream induction
of SGK-1.
Conclusion. The effects of high glucose on PTC prolifera-
tion, reduced apoptosis and increased NHE3 mRNA levels are
mediated by EGFR-dependent up-regulation of SGK-1.
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Serum glucocorticoid regulated kinase (SGK) is a
novel member of the serine/threonine kinase gene fam-
ily that was initially identified as an immediate early gene
under acute transcriptional control by serum and gluco-
corticoids [1]. It is now recognized to be activated at both
the transcriptional and posttranslational levels by a num-
ber of extracellular signals. As a result of its wide distri-
bution and regulation by diverse stimuli, it is thought that
SGK-1 is an important focal point for the convergence of
intracellular cross-talk pathways that results in changes
in proliferation and apoptosis [2]. The exact mecha-
nisms, however, by which SGK-1 is activated, and in
turn activates downstream targets, remain in many cases
unresolved.
In the kidney, in situ hybridisation has demonstrated
SGK-1 mRNA in glomeruli and the distal tubules. How-
ever, no signal above background has been previously
detected in the proximal tubule (PTC) [3, 4]. The lev-
els of SGK-1 mRNA in the glomeruli does not change
in the presence of glucocoticoids. Hence the majority of
research into SGK-1 in the kidney has focussed on the dis-
tal tubules. In the distal tubules SGK-1 is thought to be
a key mediator of aldosterone induced sodium reabsorp-
tion by the epithelial sodium channel ENaC. This involves
alterations in the ubiquitination status of the ENaC sub-
units via a mechanism that may involve SGK phospho-
rylation of Nedd4-2 [5–8]. Importantly, elevated levels of
SGK-1 transcripts have been observed in the kidneys of
both animal models of diabetes mellitus and in humans
with diabetes mellitus [9]. Indeed the activity of SGK-1
is known to be regulated by many of the factors integral
to the diabetic state, including osmotic stress [10]. The
induction of SGK-1 has been shown to confer a survival
advantage to cells exposed to osmostic stress by inhibiting
the apoptotic response [11–14] and promoting prolifera-
tion [15]. These findings together with the observation
that SGK-1 is induced by the profibrotic cytokine trans-
forming growth factor-b1 (TGF-b1) [16], suggested a
pivotal role for SGK-1 in the genesis of diabetic
nephropathy and a mechanism to explain increased
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sodium retention frequently associated with diabetic
nephropathy. To date, SGK-1 protein has not been re-
ported in the PTC of animal [3, 4], or more important,
human kidneys [10]. However, the PTC forms the bulk
of the volume of the human kidney and is involved in
the majority of renal sodium transport. Furthermore, the
activity of the prime transporter involved in the apical
reabsorption of sodium by the proximal tubule, Na+-H+
exchanger isoform 3 (NHE3), has recently been shown
to be increased by SGK-1 [17] acting via the Na+-H+
regulatory factor isoform-2 (NHERF-2) [18, 19].
In addition to its key role in the reabsorption of sodium,
the PTC has also been demonstrated pathologically to be
involved in the initial development of diabetic nephropa-
thy. In response to high glucose the PTC undergoes an
initial hyperplastic phase followed by a prolonged hyper-
trophic phase. These growth effects are due to changes
in the circulating levels and paracrine influences of var-
ious cytokines and growth factors such as TGF-b1, an-
giotensin II (Ang II) and possibly less well appreciated,
epidermal growth factor (EGF). EGF is a key prolifer-
ative growth factor that is up-regulated in the kidneys
of animals with experimentally induced diabetes mellitus
[20], where it has been shown it can promote cell growth
and regulate sodium transport via NHE3 [21].
In addition to its role in binding EGF, the EGF recep-
tor (EGFR) serves a pivotal role as a central transducer
of heterologous signaling systems as a result of transac-
tivation [22]. This transactivation of EGFR by diverse
stimuli such as G protein–coupled receptors, cytokines,
or cellular stress provides a mechanism for the EGFR
to integrate these extracellular signals and act as a relay
station to the transcriptional machinery. Both Ang II [23,
24] and aldosterone [25] are known to transactivate the
EGFR and importantly, high glucose has recently been
shown to transactivate EGFR [26].
The current study was therefore undertaken to deter-
mine the presence of SGK-1 in the PTC and to inves-
tigate the interactions between high glucose, EGF, and
SGK-1 in the PTC in the development of human diabetic
nephropathy.
METHODS
Primary culture of human PTCs
Segments of macroscopically and histologically normal
renal cortex were obtained under aseptic conditions from
patients undergoing nephrectomy for small (<6 cm) tu-
mors. Patients were accepted for inclusion into the study
if there was no history of renal or systemic disease known
to be associated with tubulointerstitial pathology. Written
informed consent was obtained from each patient prior to
surgery and ethical approval for the study was obtained
from the Royal North Shore Hospital Human Research
Ethics Committee. The methods for primary culture of
human PTCs are described in detail elsewhere [27]. In
brief, tubular fragments were derived from segments
of renal cortex by collagenase digestion and isolated
by centrifugation in 45% Percoll (Pharmacia, Uppsala,
Sweden). The PTCs were resuspended in serum-free hor-
monally defined media consisting of 1:1 (vol:vol) mixture
of Dulbecco’s modified Eagle’s medium and Hams F-12
media (DMEM/F-12) (ICN Pharmaceuticals Inc., Costa
Mesa, CA, USA), supplemented with 5 mg/mL human
transferrin, 5 mg/mL bovine insulin, 0.05 mmol/L hy-
drocortisone, 50 mmol/L prostaglandin E1, 50 nmol/L
selenium, 5 pmol/L tri-iodothyronine (all from Sigma
Chemical Co., St. Louis, MO, USA), 100 units/mL
penicillin, 100 lg/mL streptomycin, and 0.292 mg/mL
L-glutamine (PSG) (Invitrogen, New York, NY, USA).
At confluence the cells were harvested using Dispase (In-
tegrated Sciences, Sydney, Australia) and stored in liquid
nitrogen. When required, the cells were thawed and after
reaching confluence were harvested and subcultured as
below.
Cell culture
PTCs were cultured in DMEM/F-12, supplemented
with the growth factors described above and maintained
at 37◦C and 5% CO2. The effect of high glucose on SGK-
1 and NHE3 mRNA expression and the mechanisms
whereby these alterations occurred were studied. Specif-
ically the role of EGF and its receptor phosphorylation
on SGK-1 induced growth and function were studied.
PTCs were plated at a density of 2.5 × 105 per
well maintained in media containing DMEM/F-12, sele-
nium/T3, transferrin, PSG in 5 mmol/L glucose (control
conditions) prior to 24-hour exposure to either control
conditions, 25 mmol/L glucose or 10 ng/mL EGF (Collab-
orative Research Inc., Bedford, MA, USA). This concen-
tration of EGF has previously been demonstrated to ex-
ert growth and functional abnormalities in PTCs [28]. As
EGF was demonstrated to increase SGK-1 (see Results
section), the neutralizing effect of the EGFR inhibitors
AG1478 (40 nmol/L) (Calbiochem, EMD Biosciences, La
Jolla, CA, USA) and PKI166 [29], a novel EGFR tyrosine
kinase inhibitor of the pyrrolo-pyrimidine class [30], on
EGF and high glucose induced increased SGK-1 was as-
sessed in cells simultaneously exposed to high glucose or
EGF, in the concentrations reported above. PKI166 was
synthesized in the laboratories of NIBR (Novartis Insti-
tutes for Biomedical Research, Research Oncology) and
was provided by NIBR for the purpose of this study. Both
PKI166 and AG1478 were similarly effective in reducing
high glucose and EGF-induced increases in SGK protein.
However, PKI166 was considered highly specific with the
inhibition constant (IC50) for the EGFR being 0.7 nmol/L
[30]. Hence, this compound was used in further experi-
ments. An initial dose response experiment of PKI166 in
neutralizing the proliferative effect of EGF 10 ng/mL in
control conditions was undertaken. This defined 4 lmol/L
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Table 1. Primer sequences for competitive PCR
cDNA Primer sense Primer sequence 5′ to 3′ Target size Competitor size
NHE3 Sense GTTCTTCACCGTCATCTTCCA 444 309
Antisense AGCGCTGACATTTTCTCTCAG
LAS ACGCGTGACATTTTCTTCTCTCAGGGCCACGTAGCTG ATGGC
SGK-1 Sense GCCAATGGAGTTGGGGACAG 574 465
Antisense TGCCTTGGGCTACCTGCATT
LAS TGCCTTGGGCTACCTGCATTGCACAACATCCTTC TGTC
LAS is long antisense primer.
PKI166 as the optimal dose to reverse EGF-induced pro-
liferation, and thus was used in subsequent experiments.
Cell count
In order to confirm the biological activity of EGF, PTCs
were grown to 90% confluence, quiesced in control con-
ditions for 24 hours, and then exposed to 10 ng/mL EGF
or a combination of 10 ng/mL EGF and 4 lmol/L PKI166
for 24 hours. Cells were then trypsinized and manually
counted using a hemocytometer.
SGK-1 and NHE3 competitive reverse
transcription-polymerase chain reaction (RT-PCR)
Competitive RT-PCR was performed to determine the
changes in SGK-1 and NHE3 mRNA expression level in-
duced by exposure to treatments described above. Total
RNA was extracted using RNeasy Kit (Qiagen, Victo-
ria, Australia), according to manufacturer’s instructions.
RNA was reverse transcribed using the Superscript II
Reverse Transcriptase kit (Invitrogen). Sense and com-
petitive primer sequences are as detailed for both NHE3
and SGK-1 in Table 1.
PCR reactions were performed on cDNA using the
sense and competitor primers and the products gel pu-
rified and quantitated. For the PCR reaction, the com-
petitor cDNA was used at concentrations of 0.2, 0.5, 1.5,
4.6, and 13.7 fmol/L. The thermal profile consisted of
denaturation at 94◦C for 1 minute, annealing at 60◦C
for 1 12 minutes, and extension at 72
◦C for 1 12 minutes,
for 30 cycles using Expand High Fidelity PCR System
(Roche, Mannheim, Germany). The products were run
on a 2% agarose gel stained with ethidium bromide and
photographed. The photograph was then scanned into
a computer and the relative intensities of the individ-
ual bands quantitated using NIH Image software version
1.60. It was considered that the concentration of the com-
petitor is equivalent to the concentration of the message
for the target gene.
Western blotting
In order to detect changes in the levels of protein
for SGK-1 or NHE3 following exposure to EGF or
high glucose, in the presence or absence of PKI166
or cells transfected with SGK-1 (see below), we used
standard Western blotting techniques. Western blots
were performed on Triton X-100 soluble fractions of cells
for detection of SGK-1 and NHE3. Protein concentra-
tions were determined using the Bio-Rad protein assay
(Hercules, CA, USA). Equal amounts of protein were
loaded and all samples were subjected to run on sodium
dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) under reducing conditions and transferred
to Hybond enhanced chemiluminescence (ECL) ni-
trocellulose membrane (Amersham Pharmaceuticals,
Bucks, UK). The membranes were blocked in 5% skim
milk, and incubated with pan-SGK antibody (Cell Signal-
ing, Beverly, MA, USA) or NHE3 antibody (Chemicon
International Inc., Temulca, CA, USA) overnight at 4◦C
followed by incubation with antirabbit IgG (Fc) alkaline
phosphatase (AP) conjugate antibody (Promega,
Madison, WI, USA) for 1 hour at room temperature.
Protein was detected using ECL Kit (Amersham Phar-
maceuticals). The bands corresponding to SGK-1 (48.5
kD) and NHE3 (100 kD) were quantitated using NIH
Image software version 1.60.
Western blot analysis was additionally performed as
described above to determine whether high glucose and
overexpression of SGK-1 induced EGF protein in PTCs,
using an EGF antibody (Chemicon International, Inc.).
EGFR phosphorylation
The phosphorylation of the EGFR by high glucose
was determined by flow cytometry after specific label-
ing with phospho-EGFR antibody (Cell Signaling). In
brief, cultured PTCs were detached from the cell cul-
ture vessel with trypsin, washed in phosphate-buffered
saline (PBS) and fixed in 0.5% formaldehyde at 1 × 106
cells/mL for 10 minutes at 37◦C. After two washes in PBS,
cells were permeabilized using 0.1% Triton X-100 then
subsequently labeled with phospho-EGFR antibody for
1 hour at room temperature. Following two subsequent
washes, cells were labeled with fluorescein isothiocyanate
(FITC)-conjugated goat antirabbit IgG (BD Biosciences
Pharmingen, San Diego, CA, USA) overnight. The cells
were washed twice before flow cytometric analysis using a
FACScan flow cytometer (Becton Dickinson, Mountain
View, CA, USA). Data are presented as percentage of
mean fluorescent intensity (± SEM) compared to control
(5 mmol/L glucose). An initial time course demonstrated
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phosphorylation of the EGFR within 10 minutes that was
maximal at 24 hours, persisting to 48 hours (Fig. 3D). This
became the basis of the time frame of the immunoprecip-
itation.
Immunoprecipitation
To confirm phosphorylation of the EGFR in response
to high glucose, standard immunoprecipitation methods
were used. Briefly, 50 lg protein was used per experi-
mental condition, made up to 500 lL in PBS. A 1:100
dilution of the phospho-EGFR antibody (Cell Signal-
ing) was added to this protein and incubated for 2 hours
at 4◦C. After this time, 40 lL of EZview agarose beads
(Sigma Chemical Co.) was added to each condition and
incubated overnight at 4◦C. The protein complexes were
then washed twice in cold PBS. The samples were boiled
in SDS-PAGE sample buffer for 10 minutes, then run
on a gel by standard Western blot procedures as de-
scribed above. An antiphosphotyrosine antibody PY20
(BD Transduction Laboratories, San Jose, CA, USA) was
used to detect phosphorylated EGFR.
In vivo experiments
In order to determine SGK-1 expression in an in
vivo model of diabetes mellitus we localized and quan-
titated renal SGK-1 expression in an animal model of
streptozotocin-induced diabetes mellitus. This model has
been previously validated for study in diabetic nephropa-
thy [31]. SGK-1 mRNA was then assessed by in situ hy-
bridization as previously described [31], quantitated by
densitometric analysis, and expressed as cpm/unit area
[32]. Experimental procedures adhered to the guidelines
of the National Health and Medical Research Council of
Australia’s Code of the Care and Use of Animals for sci-
entific purposes and approved by St Vincent’s Hospital
Animal Ethics Committee, Melbourne, Australia. Eight
animals were utilized in each experimental group.
SGK-1 transfection
The functional effects of increased SGK-1 expression
were determined by overexpressing SGK-1 in PTCs.
PTCs were plated on day 1 at 1 × 105 cells per well.
The next day, cells were transfected with hemagglutinin
(HA)-tagged SGK-1, empty vector [phosphorylated cy-
tomegalovirus (p-CMV)], or dominant-negative SGK-1
(plasmids purchased from Dr. M. Peggie, The Univer-
sity of Dundee, Scotland) using the Fugene-6 transfec-
tion reagent (Roche, Indianapolis, IN, USA). Efficiency
of transfection was assessed by flow cytometry after spe-
cific labeling with an HA antibody (Cell Signaling) using
a protocol identical to that used for assessment of EGFR
phosphorylation detailed above. This suggested a trans-
fection efficiency of 60% to 70%. No difference was ob-
served between cells transfected with the empty vector
and dominant-negative SGK-1; therefore, control exper-
iments contained only empty vector. Briefly, Fugene-6
and SGK-1 DNA was added to serum-free media, and
incubated at room temperature for 45 minutes, the re-
action was added drop wise to each well, and the cells
were then incubated at 37◦C, 5% CO2 for a total time
of 24 hours. Briefly, to extract protein from treated cells,
the cells were washed twice with cold PBS, then lysed
with 50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl,
5 mmol/L ethylenediaminetetraacetic acid (EDTA), 20
mmol/L sodium orthovanadate, and 0.5% Triton X-100
with proteinase inhibitor cocktail “Complete” (Roche
Diagnostics, Mannheim, Germany) for 20 minutess, fol-
lowed by centrifugation at 10,000 × g for 10 minutes
at 4◦C. In order to determine SGK protein expression
changes in transfected cells, cell lysates were used for
standard Western blot analysis, as per the methods de-
scribed above.
Functional consequences of SGK-1 overexpression
Cell count and protein expression. Cell count and hy-
pertrophy were determined as detailed above. In addition
[3H]-thymidine incorporation was measured. In brief, the
cells were exposed to 1 lCi/well of (methyl-3H) thymi-
dine (Amersham, Bucks, England) in the final 4 hours
of each 24-hour time point. The cells were then washed
four times in PBS, solubilized in 0.2 mol/L NaOH, added
to scintillant (Ecolite, ICN, Costa Mesa, CA, USA) and
the samples counted in a b counter (LKB Wallac, Turku,
Finland). Results were expressed as [3H]-thymidine in-
corporation per cell as a percentage compared to control
values.
Cell cycle analysis. PTCs were transfected as described
above. Twenty-four hours after transfection, cell super-
natant and cells were harvested, resuspended in 500 lL
70% ethanol to permeabilize the cell membrane. The
cells were then spun down, washed with PBS twice. They
were then resuspended in 400 lL PBS, 50 lL RNAse
(10 mg/mL), and 50 lL propidium iodide (0.5mg/mL) (all
purchased from Sigma Chemical Co.). The cells were in-
cubated in the dark at 4◦C for at least 1 hour. The S phase
and apoptotic population of the cell cycle were deter-
mined by flow cytometry using a FACScan flow cytometer
(Becton Dickinson). The propidium iodide fluorescence
of individual nuclei and the forward and side scatter were
all measured using identical instrument settings with a
minimum of 20,000 events.
Apoptosis studies. To assess the role of SGK-1 in
apoptosis, PTCs were plated and transfected as above.
Twenty-four hours after transfection, apoptosis was in-
duced by treating transfected and control cells with 150
mmol/L sodium azide [33]. Cells were then collected and
processed for cell cycle analysis using the FACScan flow
Saad and Stevens et al: SGK-1 interacts with EGF receptor in diabetic nephropathy 989
cytometer as described above. Apoptosis was confirmed
by flow cytometry using CaspACE FITC-VAD-FMK la-
beling (Promega).
NHE3 Competitive RT-PCR. The effect of overex-
pression of SGK-1 on NHE3 mRNA expression was de-
termined by competitive RT-PCR as detailed above.
SGK-1 induced phosphorylation of the EGFR. The
effect of overexpression of SGK-1 on EGFR phospho-
rylation was determined by flow cytometry after specific
labeling with the phospho-EGFR as detailed above.
Statistical analysis
In vitro experiments were performed at least in tripli-
cate on a minimum of three different cell culture prepa-
rations. Unless otherwise stated, results are expressed as
a percentage of the control (cells grown in 5 mmol/L
glucose). Statistical comparisons between groups were
made by analysis of variance (ANOVA) or paired t tests
where appropriate. Analyses were performed using the
software package, Statview version 4.5 (Abacus Concepts
Inc., Berkley, CA, USA). P values less than 0.05 were
considered significant.
RESULTS
EGF effects in PTCs
A significant proliferative response was induced in
PTCs exposed to 10 ng/mL EGF to 119 ± 5% of control
values (P < 0.01). This response was completely reversed
in the presence of the EGFR blocker PKI166 to 93.6 ±
5% of control values (P < 0.01), confirming the biologic
activity of PKI166. The expression of the phospho-EGFR
was increased from 50% under control conditions to 63%
in the presence of 10 ng/mL EGF. This phosphorylation
was attenuated in the presence of EGF and PKI166 to
52%, hence similar to control levels. These results con-
firmed that the EGFR is present and constitutively active
in PTCs. It is further activated by EGF in human PTCs
to induce a proliferative response.
SGK-1 mRNA and protein expression following
exposure to EGF and high glucose
SGK-1 protein was expressed under basal conditions
with synthesis presumed downstream of the EGFR phos-
phorylation as protein expression was significantly atten-
uated in the presence of the EGFR blocker PKI166 to
24.2 ± 6.2% (P < 0.0001). SGK-1 mRNA was signifi-
cantly increased following 24-hour exposure to EGF to
216 ± 36% of control values (P < 0.002), which was
completely reversed by PKI166 to control levels (115 ±
30%) (Fig. 1A). The up-regulated message was clearly
translated into increased protein (174 ± 23% of control
values) (P < 0.02) as demonstrated in the Western Blot
and graphically represented in Figure 1B. The increase in
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Fig. 1. Effect of epidermal growth factor (EGF) on serum glucocor-
ticoid regulated kinase-1 (SGK-1). (A) SGK-1 mRNA expression in
proximal tubular cells (PTCs). SGK-1 mRNA levels were determined
in control (5 mmol/L glucose) conditions and in response to EGF (10
ng/mL) in the presence and absence of PKI166 (4 lmol/L). ∗P < 0.002 vs.
control. (B) Western Blot analysis of PTC SGK-1 protein expression
and graphical representation of Western blot of PTC SGK-1 protein
expression in control (5 mmol/L glucose); EGF (10 ng/mL); EGF (10
ng/mL) + PKI166 (4 lmol/L). ∗P < 0.02 vs. control.
SGK-1 protein induced by EGF returned to baseline in
the presence of PKI166 to 85 ± 17% of control values
(P < 0.005), confirming the regulation of SGK-1 by
EGFR phosphorylation. PKI166 had no effect on SGK-1
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Fig. 2. Effect of high glucose on serum glucocorticoid regulated kinase-
1 (SGK-1). (A) SGK-1 mRNA expression in control (5 mmol/L) and
high (25 mmol/L) glucose ± PKI166 (4 lmol/L) ∗P < 0.005 vs. control.
(B) Western Blot of proximal tubule cell (PTC) SGK-1 protein expres-
sion and graphic representation of Western blot of PTC SGK-1 protein
expression in control (5 mmol/L), high (25 mmol/L) glucose, and 25
mmol/L glucose + PKI166 (4 lmol/L). ∗P < 0.02 vs. control.
protein expression under control conditions (5 mmol/L
glucose).
High glucose also induced an increase in SGK-1
mRNA expression to 149 ± 13% of control values (P <
0.005) that was also completely reversed in the pres-
ence of PKI166, suggesting that the up-regulation of
SGK-1 in high glucose conditions occurs through an
EGF-dependent mechanism (Fig. 2A). This was con-
firmed at the level of protein expression as the high
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Fig. 3. Effect of serum glucocorticoid regulated kinase (SGK) and 25
mmol/L glucose on epidermal growth factor receptor (EGFR) phospho-
rylation. (A) Flow cytometry. Increased phosphorylation of the EGFR
in proximal tubule cell (PTC) exposed to high (25 mmol/L) glucose in
the presence and absence of PKI166 (4 lmol/L). ∗P < 0.01 vs. control.
(B) Immunoprecipitation and subsequent Western blotting confirm-
ing increased phosphorylation of the EGFR in high glucose (P < 0.01
vs. 5 mmol/L glucose) and attenuation in the presence of PKI166 (4
lmol/L). (C) Flow cytometry. Increased phosphorylation of the EGFR
expression in PTC transfected with SGK-1 in the presence and ab-
sence of PKI166 (4 lmol/L) ∗P < 0.01 vs. control cells [transfected with
phosphorylated cytomegalovirus (p-CMV) vector]. (D) Time course
for phospho-EGFR. Cells were treated with high glucose (25 mmol/L)
showing phosphorylation of the EGFR within 10 minutes that was max-
imal at 24 hours, persisting to 48 hours.
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Fig. 4. Effect of high glucose and epidermal
growth factor (EGF) on sodium hydrogen ex-
changer (NHE3). (A) Proximal tubule cell
(PTC) NHE3 mRNA expression in control (5
mmol/L) glucose ± PKI166 (4 lmol/L); high
(25 mmol/L) glucose ± PKI166 (4 lmol/L);
and EGF (10 ng/mL) ± PKI166 (4 lmol/L).
∗P < 0.05 vs. control values. (B) Western blot
analysis of PTC NHE3 protein expression in
control (5 mmol/L), high (25 mmol/L) glucose,
and EGF (10 ng/mL) + PKI166 (4 lmol/L). ∗P
< 0.05 vs. control.
glucose induced up-regulation of SGK-1 mRNA was
translated into protein (180 ± 21%) of control values (P
< 0.02) as shown in the representative Western Blot and
represented graphically in Figure 2B.
EGF protein expression and EGFR phosphorylation
following exposure to EGF, high glucose, and
overexpression of SGK-1
Flow cytometry and immunoprecipitation with subse-
quent Western blotting of the phospho-EGFR demon-
strated constitutive phosphorylation of the EGFR under
control conditions which could be attenuated to 75.5 ±
13.5% (P < 0.05) of control in the presence of EGFR
blockade using PKI166. An increase in the phospho-
EGFR was observed after exposure to high glucose to
124 ± 6% of control values (P < 0.01) (Fig. 3A), which
was confirmed by immunoprecipitation and subsequent
Western blotting (Fig. 3B) (112.5% ± 2.12 of control)
(P < 0.01). An increase in the phospho EGFR was also
observed in cells overexpressing SGK-1 protein to 145 ±
2% (P < 0.01) of the levels of EGFR phosphorylation
observed under control conditions (Fig. 3C). The level
of phosphorylation of the EGFR in the presence of high
glucose and overexpression of SGK-1 was attenuated in
the presence of PKI166 to control values (Fig. 3A and
C). EGF protein was not detected by Western blotting
in PTCs under control or high glucose conditions which
is consistent with prior studies [34]. Hence, these results
suggest that high glucose induced SGK-1 can activate the
EGFR, independent of local up-regulation of EGF pro-
tein, potentially amplifying the functional response.
NHE3 mRNA and protein expression in response to EGF
and high glucose
As illustrated in Figure 4A, NHE3 mRNA was signif-
icantly increased by EGF to 168 ± 16% (P < 0.05) and
high glucose to 140 ± 15% (P < 0.05) of control values.
The EGF and high glucose–induced increases in NHE3
mRNA were reversed in the presence of PKI166 (Fig. 4).
PKI166 also reduced the NHE3 mRNA and protein ex-
pression observed under control conditions to 33 ± 1%
(P < 0.002) and 72 ± 10% (P < 0.05) of control values
suggesting that EGF is involved in the proximal tubu-
lar reabsorption of sodium through NHE3 under control
conditions.
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SGK-1 expression in in vivo models of diabetes mellitus
Diabetic rats gained significantly less body weight
(343.8 ± 4 g) than their respective controls (442.3 ± 2 g)
(P < 0.05). All diabetic rats were similarly hyperglycemic,
while systolic blood pressure was not different between
control (131.3 ± 2.7 mm Hg) or diabetic rats (139.2 ± 5
mm Hg).
SGK-1 gene expression was significantly increased in
the kidneys of diabetic rats compared to vehicle treated
control rats (P < 0.005) (Fig. 5). The oral administration
of PKI166 for 3 weeks in diabetic rats resulted in a 51%
reduction in SGK-1 gene expression in the kidney (P <
0.001) (Fig. 5). These results were confirmed by in situ
hybridization (Fig. 6), where an up-regulation of SGK-1
mRNA expression was clearly demonstrated in the kid-
neys of diabetic animals and reversed with PKI166.
Assessment of the functional consequences of increased
SGK-1 expression
The functional consequences of SGK-1 are illustrated
in Figure 7. Overexpression of SGK-1 increased cell pro-
liferation as indicated by the increase in [3H]-thymidine
incorporation to 181 ± 6% of control values (P < 0.01)
(Fig. 7A). The proliferative response was supported by
the flow cytometry (Fig. 7B) demonstrating an accelera-
tion through the cell cycle with an increase in the num-
ber of cells in the S phase of the cycle to 203 ± 1% of
that observed under control conditions (P < 0.0001). As
expected, exposure to sodium azide induced a marked
apoptotic response with 33.6% of cells in the pre-G1
phase of the cell cycle (Fig. 7C). This was reduced to
10.66% in cells overexpressing SGK-1, demonstrating
that SGK-1 exerts a specific anti-apoptotic effect in the
PTC. The increase in cells in the S phase of the cell cy-
cle following SGK-1 overexpression was again confirmed
in these experiments, being 198% of the control cells
treated with sodium azide (Fig. 7C). This data was con-
firmed by flow cytometry using CaspACE staining (data
not shown). Over-expression of SGK-1 in PTCs increased
NHE3 mRNA to 245 ± 28% of control values (P < 0.01)
(Fig. 7D).
DISCUSSION
This study clearly demonstrates that SGK-1 is ex-
pressed in the human PTC and is physiologically active. It
elucidates the key role that SGK-1 plays in mediating the
increased proliferation, reduced apoptosis, and increased
transcription of NHE3 under hyperglycaemic conditions,
which have been previously attributed to an increase in
EGF action in the kidney [20]. It specifically shows that
high glucose increases the expression of SGK-1 which is
is blocked by the EGFR blocker, PKI166. The effects of
high glucose are mimicked by the overexpression of SGK-
i ii
iii iv
A
Fig. 5. Serum glucocorticoid regulated kinase-1 (SGK-1) expression
in in vivo models of diabetes mellitus. (A) Pseudocolorized autoradio-
graphs of SGK-1 gene expression in the kidney of control (panel i), con-
trol + PKI166 (panel ii), diabetes (panel iii), and diabetes + PKI166
(panel iv). Cortical SGK-1 mRNA was reduced with PKI166 in both
control and diabetic rat kidneys. Red is intense expression; blue green
is low level of expression of SGK-1. (B) Quantitation of SGK-1 gene
expression in control and diabetic rats, with and without oral treatment
with PKI166. ∗P < 0.005 for diabetic animals vs. control animals; #P <
0.001 for diabetic animals vs. diabetic animals treated with PKI166.
1. Both result in an increase in tubular cell proliferation
[34] and NHE3 expression [35]. Furthermore, it is impor-
tant to note that increased tubular cell number not only
involves an increase in proliferation, but also a reduction
in the rates of apoptosis. This current study highlights the
antiapoptotic property of SGK-1 in this renal cell sys-
tem. A novel finding in this study is that in both PTCs
in culture and in an in vivo model of diabetic nephropa-
thy, the effects of glucose are highly dependent on the
activation of the EGFR. We show that blocking the
EGFR reverses the increase in SGK in response to high
glucose and abolishes the high glucose–induced changes
Saad and Stevens et al: SGK-1 interacts with EGF receptor in diabetic nephropathy 993
*
Cont Veh Cont PKI166 Diab Veh Diab PKI166
0.0E+00
1.0E+07
2.0E+07cp
m
/u
ni
t a
re
a 3.0E+07
4.0E+07
5.0E+07
B
Fig. 5. (continued)
Fig. 6. Representative photomicrographs
of serum glucocorticoid regulated kinase-1
(SGK-1) gene expression in the kidney cortex
from control (A), control + PKI166 (B),
diabetes (C), and diabetes + PKI166 (D). In
control and PKI166-treated kidneys (A, B,
and D), SGK-1 mRNA was barely detected,
while in animals with diabetes (C) there was
associated abundant SGK-1 gene expression
within the cortical tubules (magnification
×400).
in PTC cell number and NHE3 mRNA expression. These
results have implications for the development of hyper-
tension and the development of diabetic nephropathy.
Prior studies have suggested that SGK-1 is up-
regulated in both animal models and patients with
diabetes mellitus [9, 10]. In vitro studies in mouse 3T3
fibroblasts exposed to 30 mmol/L D-glucose have demon-
strated a twofold increase in the expression of SGK
mRNA within 8 hours [10]. An additional 55% increase
in mRNA for SGK occurred in endothelial cells within
2 hours of exposure to 50 mmol/L glucose, an effect
attributed to be due to hyperosmolality [10], which is
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transfected Fig. 7. Functional consequences of up-
regulation of serum glucocorticoid regulated
kinase-1 (SGK-1) in proximal tubule cells
(PTCs). (A) [3H]-thymidine incorpora-
tion in control [(empty phosphorylated
cytomegalovirus (p-CMV) vector] and PTC
transfected with SGK-1. ∗P < 0.01 vs. control.
(B) Representative flow cytometry graphs
demonstrating an increase in cells in the
S phase in PTC overexpressing SGK-1
[P < 0.001 vs. control (empty vector)].
(C) Representative flow cytometry graphs
demonstrating an increase in apoptosis
induced by sodium azide, which is reduced
in cells transfected with SGK-1. (D) Sodium
hydrogen exchanger (NHE3) mRNA in
control (empty vector) and PTC transfected
with SGK-1. ∗P < 0.01 vs. control.
consistent with recent data suggesting that SGK-1 plays a
significant role in the regulation of cellular osmotic stress
and the subsequent regulation of cell volume [10]. How-
ever, to date, no studies have examined SGK-1 in PTC,
which undergo increased proliferation and transport in
association with diabetes.
The previously demonstrated association between
diabetic nephropathy [20], EGF-induced alterations in
tubular growth and transport [21], and the recent demon-
stration that the EGFR can be transactivated by multiple
pathways [22] has been further explored in the present
study. The distribution of EGF protein has been pre-
viously confirmed to be absent in the PTC and largely
expressed in the distal segments of the kidney, where
it is increased in the early stages of experimental dia-
betes [20]. These findings are consistent with the findings
of the present study where no detectable EGF protein
was present in the cultured PTCs under control or high
glucose conditions. In contrast, the EGFR is expressed
widely in the PTC and well known to mediate growth re-
sponses in the PTC. However, it is clear that the EGFR
can be activated independent of EGF itself. In particular
aldosterone, one of the hormones originally recognized
as playing a key role in SGK-induced transport is now rec-
ognized to mediate effects on sodium transporters in the
PTC through EGF-dependent mechanisms [25]. The re-
sults of the present the in vitro and in vivo studies are com-
plementary as both consistently demonstrate that high
glucose increases SGK-1 and that inhibition of the EGFR
tyrosine kinase phosphorylation attenuates this increase.
This implies that glucose stimulates the phosphoryla-
tion of the EGFR which in turn increases SGK-1. We
have clearly shown that SGK-1 attenuates proapoptotic
stimuli while stimulating progression through the cell cy-
cle. Therefore the mitogenic and antiapoptotic functions
of EGF may be mediated by SGK-1.
The critical role of the EGFR in up-regulation of
SGK-1 has not previously been considered. Indeed, one
prior study investigating SGK expression in 3T3 cells re-
ported that cytokines responsible for a sustained activa-
tion of the extracellular-related kinase (ERK) mitogen
activated protein (MAP) kinase pathway induced SGK
more strongly than EGF, which only induced a transient
activation of ERK MAP kinase [35]. Clearly our results
differ, and suggest that factors inherent in the diabetic
state, specifically high glucose as shown in this study, in-
duce SGK-1, which is completely reversed in the presence
of the highly specific EGFR blocker PKI166. Although
we did not investigate the ERK MAP kinase pathway in
the present study, we have previously demonstrated in an
alternative model of human endothelial cells that both the
ERK pathway and the p38 MAP kinase pathways were
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up-regulated over a 72-hour period of high glucose expo-
sure [36]. As SGK-1 induction has also been reported to
be induced by a p38 MAP kinase–dependent mechanism
it is possible that several upstream mediators induced by
high glucose, including osmolality [10], may influence the
SGK pathways to a variable extent in different cell types
and models.
To define the role of SGK-1 we overexpressed
SGK-1 in human PTCs and demonstrated that it con-
ferred a growth promoting effect and protected against
proapoptotic stimuli, as has previosuly been demon-
strated in other model systems [12, 14]. Our results
demonstrating that SGK-1 overexpression also induced
EGFR phosphorylation are also in keeping with the pre-
vious observation that phosphorylation of the EGFR in-
duces accelerated progression through the cell cycle [37]
and protects cells from apoptosis. This has also been
shown to be via a MAPK kinase–dependent pathway and
independent of protein kinase C, which is also known to
be up-regulated in the diabetic kidney. From our studies it
is likely that a key function of SGK-1 is to modify sodium
transport in the proximal tubule. We have clearly demon-
strated an up-regulation of NHE3 mRNA and protein,
which in all prior studies undertaken in our laboratory
this has translated into an increase in NHE activity [38].
To date enhanced sodium transport has been most widely
characterised in the distal tubule with SGK-1 known to in-
duce sodium reabsorption through the epithelial sodium
channel ENaC, by influencing key regulatory proteins
such as Nedd4 [5–8]. However, it has recently been rec-
ognized that SGK-1 may regulate sodium reabsorption
through enhanced sodium hydrogen exchange (NHE3)
activity. It has been suggested that these transporters are
activated by SGK-1 as a volume regulatory response due
to the alterations in cell volume inherent in exposure to
high glucose [39]. It has more recently been shown that
SGK-1 plays a key role in regulating the glucocorticoid-
induced up-regulation of NHE3 activity by interacting
with the postsynaptic density protein (PDZ) domains of
NHERF2, which functions to anchor NHE3 to ezrin in the
formation of localized signaling complexes at the plasma
membrane [17, 40]. In addition to the studies that show
that SGK-1 can modulate the function of SGK-1 [17],
we now show that increased SGK-1 itself can up-regulate
the expression of NHE3 mRNA mediated through an
EGFR-dependent mechanism. This may well contribute
to the well recognized increase in sodium reabsorption in
the PTC in diabetic nephropathy.
CONCLUSION
Our findings suggest that high glucose activates the
EGFR in a nonligand-dependent manner, which then
up-regulates SGK-1. Hence, the abnormalities in tubular
cell growth known to occur in diabetic nephropathy and
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the increased NHE3 expression and tubular sodium reab-
sorption known to be responsible for the observed hyper-
tension are likely to occur through an EGFR-dependent
mechanism. These results suggest that SGK-1, or alter-
natively phospho-EGFR may be potential novel targets
that may independently impact on the development of
diabetic nephropathy.
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